Respironics Has Sweet Dreams In November As Stock Advances
This article was originally published in The Gray Sheet
Executive Summary
Increased investor visibility, strong obstructive sleep apnea sales and a smooth CEO transition helped Respironics achieve a 9.2% stock gain in November
You may also be interested in...
Respironics Class I recall
Firm announces voluntary recall of 5,293 ComfortGel sleep apnea nasal masks distributed from Sept. 5-15 because some products were shipped without an exhalation port for carbon dioxide. Without the port, patients could experience oxygen deficiency or suffocation, the Murrysville, Penn. firm says Dec. 3. Respironics alerted FDA of the issue in September, and maintains that 82% of the recalled masks have returned with less than 3% affected. The company initiated a Class I recall for computer-controlled ventilators this summer (1"The Gray Sheet" July 7, 2003, In Brief)...
Gen/Surg Panel Okays Dermal Fillers 6-3; Minority Patient Studies Proposed
Medicis/Q-Med plan to conduct a 100-patient, Phase IV study to evaluate Restylane non-animal stabilized hyaluronic acid-based wrinkle gel in "people of color," in accordance with FDA panel recommendations
Given Imaging Targeting M2A Reimbursement Beyond Obscure Bleeding
A BlueCross BlueShield TEC assessment supporting capsule endoscopy for Crohn's disease diagnosis furthers Given Imaging's efforts to obtain coverage for indications beyond obscure bleeding